{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-22-000028","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.784813+00:00","generated_at":"2026-06-26T20:01:13.229299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024","bullets":["Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.","Net loss of $10.5M for FY2021 vs net income of $6.6M in 2020; R&D expenses $3.8M, G&A $3.6M.","Closed $31.25M private placement in Dec 2021; $28.75M IPO earlier; pipeline includes three Phase 2 ONA-XR trials and CLDN6 bsAb candidate selection in 2022.","Appointed Christopher Beck as SVP Operations and Mark Fletcher as VP R&D in Jan 2022.","Preliminary data expected mid-2022 from first-line metastatic breast cancer and recurrent endometrial cancer trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-22-000028","json":"https://secwatch.observer/filing/0001842952-22-000028.json","markdown":"https://secwatch.observer/filing/0001842952-22-000028.md","text":"https://secwatch.observer/filing/0001842952-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000028/0001842952-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000028/cntx-20220323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:01:13.229299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}